55
Suresh Pichandi et al. / Int J Cur Sci Res. 2011; 1(2): 47 - 56.
In short, the administration of rosuvastatin and atrovastatin was
found to be more effective in the treatment of hyperlipidaemic
patients than that of pravastatin. Although flavostatin also had a
profound effect, the dosage was high compared to other statins.
Hence its effectiveness compared to rosuvastatin and atrovastatin
need to be further investigated.
Rosuvastatin and Atrovastatin can be more effective in reducing
hyperlipidemia compared to other classes of statin drugs and thus
further reduce the risk of cardiovascular disease in such
patients.In addition to that,Rosuvasatin had less side effects in
patients as compared to atrovastatin and can be defined as the
most effective among the statin class of drugs.
13.References
[1] Paulweber B.Statins in primary prevention of coronary heart disease. Wien
Med Wochenschr. 1999;149:129-138.
[2] Vasa M, Fichtlscherer S, Adler K. Increase in circulating endothelial
progenitor cells by statin therapy in patients with stable coronary artery
disease. Circulation. 2001; 103:2885-2890.
[3] Shepherd J, Cobbe SM, Ford I. West of Scotland Coronary Prevention Study
Group. Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
[4] Christie M,Ballantyne. There are currently six statins
available—simvastatin, lovastatin, pravastatin,
atorva- statin, fluvastatin, and rosuvastatin—all of which lower LDL
cholesterol, These have each been used widely in recipients of solid
organ.2009;5:450-584.
[5] Vaughn CJ, Delanty N. Neuroprotective actions of statins in cerebral
ischemia and stroke. Stroke. 1999; 30:1969-1973.
[6] Black DM. A general assessment of the safety of HMG CoA reductase
inhibitors (statins). Curr Atheroscler Rep. 2002; 4:34-41.
[7] Durazzo AES, Machado FS, Ikeoka D, Peuch-Leao P, Caramelli B. Effect of
atorvastatin on cardiovascular events after vascular surgery. Circulation.
2002; 106:339-343.
[8] Ballantyne CM. Statins after cardiac transplantation: which statin, what
dose, and how low should we go? J Heart Lung Transplant. 2000;
19:515-517.
[9] Kobashigawa J, Katznelson S, Laks H. Effect of pravastatin in outcomes after
cardiac transplantation. N Engl J Med. 1995; 333:621-627.
[10]Wenke K, Meiser B, Thiery J. Simvastatin reduces graft vessel disease and
mortality after heart transplantation—a four year randomised trial.
Circulation. 1997; 96:1398-1402.
[11]Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature.
1990; 343:425-430.
[12] Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors.
Trends Cardiovasc Med. 2000; 10:143-148.
[13]Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose
simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in
ciclosporin-treated kidney transplant recipients: double-blind,
randomized, placebo-controlled study in 40 patients. Nephron.
1994;68:57-62.
[14] Raithatha N, Smith Richard D. Paying for statins. BMJ. 2004; 328:400-402.
[15] Jialal I, Stein D, Balis D. Effect of hydroxymethyl glutaryl coenzyme A
reductase inhibitor therapy on high sensitive C-reactive protein levels.
Circulation. 2001;103:1933-1935.
[16] Pedersen TR, Faergeman O, Kastelein JP, Olsson AG, Tikkanen MJ, Holme I.
High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention
after myocardial infarction. JAMA. 2005;294:2437-2445.
[17] Nawrocki JW,Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ,
Jones PH, Haber HE. Reduction of LDL cholesterol by 25% to 60% in
patients with primary hypercholesterolemia by atorvastatin, a new HMG-
CoA reductase inhibitor.Arterioscler Thromb Vasc Biol.1995;15 :678-682.
[18] Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone
SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary
prevention of cardiovascular disease with atorvastatin in type 2 diabetes in
the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre
randomised placebo-controlled trial.2004; 364:685-696.
[19]Tonelli M, Moye L, Sacks FM. Cholesterol and Recurrent Events (CARE) Trial
Investigators. Pravastatin for secondary prevention of cardiovascular
events in persons with mild chronic renal insufficiency. Ann Intern Med.
2003;138:98-104.
[20] Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density
lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic
review and meta-analysis. BMJ. 2003 ;326:1423-1423.
[21] Wei L, Ebrahim S, Bartlett C, Davey P D, Sullivan F M, MacDonald T M. Statin
use in the secondary prevention of coronary heart disease in primary care:
cohort study and comparison of inclusion and outcome with patients in
randomised trials. BMJ. 2005 ;330:821-822.
[22]Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999
;341:498-511.
[23] Creese A. Global trends in health care reform. World Health Forum.
1994;15(4):317-322.
[24] Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for
economic evaluation in health care. Practice, problems, and potential. Int J
Technol Assess Health Care. 1993 ;9:26-36.
[25]Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW,
McKillop JH, Packard CJ. Prevention of coronary heart disease with
pravastatin in men with hypercholesterolemia. West of Scotland Coronary
Prevention Study Group. N Engl J Med. 1995 ;333:1301-1307.
[26]D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P. Validation of the
Framingham coronary heart disease prediction scores: results of a multiple
ethnic groups investigation. JAMA. 2001 ;286:180-187.
[27] McKenney JM, Kinosian B. Economic benefits of aggressive lipid lowering: a
managed care perspective. Am J Manag Care. 1998 ;4:65-74.
[28] Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-
effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors to treat hypercholesterolemia in a primary care
setting of a managed-care organization. Clin Ther. 1997;19:582-539.
[29] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a
meta-analysis of randomized controlled trials. JAMA. 1999
;282:2340-2346.
[30] Field K, Thorogood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for
reducing coronary risk factors in primary care: which is most cost effective?
BMJ. 1995 ;310:1109-1112.
[31] Assmann G, Schulte H. Primary prevention of coronary heart disease in the
Federal Republic of Germany. Analysis of cost-effectiveness. Drugs. 1990;40
:1:33-37.
[32] Schulman KA, Kinosian B, Jacobson TA, Glick H, Willian MK, Koffer H,
Eisenberg JM. Reducing high blood cholesterol level with drugs. Cost-
effectiveness of pharmacologic management. JAMA. 1990 ;264:3025-3033.
[33] Perreault S, Levinton C, Le Lorier J. Efficacy and cost of HMG-CoA reductase
inhibitors in the treatment of patients with primary hyperlipidemia. Can J
Clin Pharmacol. 2000 ;7:144-154.